FDA
approval
· 2021-03-15
FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
Summary
The FDA approved a supplemental ANDA for a generic buprenorphine and naloxone product, manufactured by PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE)